WFG, WFO LASIK: How much HOA?

Article

Real-world data support wavefront-guided procedure with femtosecond laser flap creation

In young patients who present with low-to-moderate myopia, minimal astigmatism, and excellent optics, there is no doubt that wavefront-guided (WFG) LASIK with femtosecond laser flap creation is the refractive surgery procedure of choice, according to Dr Steven C. Schallhorn.

A database search was performed to find patients who matched a sample patient with the following baseline criteria: male gender, 28 years of age, myopia –3.5 to –4 D, cylinder <1 D, and a minimum follow-up of 1 month; 28 eyes of 20 patients were identified.

"These are phenomenal outcomes from a relevant, real-world population, and the data are consistent with my opinion that WFG LASIK is the best procedure to give the best possible outcome for patients represented by this specific clinical scenario," Dr Schallhorn said. "WFG LASIK gives the best visual quality with the least induction of higher-order aberration (HOA), and the latter is especially important in the situation where patients have very low pre-existing wavefront error. These individuals come in with excellent visual quality and demand it postoperatively."

In 2009, more than 90000 eyes were treated at an Optical Express centre. The 28 eyes identified after applying the search criteria had a mean manifest sphere of –3.77 D, mean manifest cylinder of –0.42 D, mean best-corrected visual acuity (BCVA) of 20/16, and mean low-light pupil diameter of 6.4 mm.

All had flap creation using the same femtosecond laser [IntraLase FS 60, Abbott Medical Optics (AMO)] and WFG treatment with the same excimer laser (VISX CustomVue, AMO) using a 6mm optical zone and 8mm transition zone.

At 1 month, mean ± SD manifest sphere was +0.05 ± 0.23 D, mean ± SD manifest cylinder was –0.12 ± 0.17 D, and mean UCVA was 20/16+1.

"Zero refraction was targeted for both manifest sphere and cylinder in these eyes, and for both endpoints, the achieved was extraordinarily close to the intended using the WFG procedure," Dr Schallhorn said.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
© 2025 MJH Life Sciences

All rights reserved.